Lv2
110 积分 2023-07-18 加入
Comparing the EORTC QLQ-LC13, EORTC QLQ-LC29, and the FACT-L for assessment of quality of life in patients with lung cancer - an updated systematic review
19小时前
已完结
Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses
24天前
已完结
The 2023 Canadian Cardiovascular Society Clinical Practice Update on Management of the Patient With a Prolonged QT Interval
25天前
已完结
Arterial and Venous Thrombosis in Cancer Patients
1个月前
已完结
Lorlatinib-associated weight gain and dyslipidaemia: A retrospective analysis and implications for future care
1个月前
已完结
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
1个月前
已完结
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
1个月前
已完结
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
1个月前
已完结
Abstract PR003: Repotrectinib in patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Update from the pivotal phase 1/2 TRIDENT-1 trial
1个月前
已关闭
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
2个月前
已完结
皖公网安备34019202002308
